Incidence and prognostic significance of karyotype abnormalities in de novo primary myelodysplastic syndromes: a study on 331 patients from a single institution.
about
Validation of the new comprehensive cytogenetic scoring system (NCCSS) on 630 consecutive de novo MDS patients from a single institution.Efficacy and safety of lenalidomide in patients with myelodysplastic syndrome with chromosome 5q deletion.Clinical relevance of cytogenetics in myelodysplastic syndromes.A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide.Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes.Update on the pharmacotherapy for myelodysplastic syndromes.The molecular pathogenesis of the myelodysplastic syndromes.Recent Advances in the 5q- Syndrome.Myelodysplastic Syndromes: Updates and Nuances.Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome.The 5q deletion size in myeloid malignancies is correlated to additional chromosomal aberrations and to TP53 mutations.How Ribosomes Translate Cancer.Better prognosis for patients with del(7q) than for patients with monosomy 7 in myelodysplastic syndrome.World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes.Dramatic response in the dependency to transfusion after low doses of lenalidomide treatment in a 5q-syndrome patient: a case report.High Incidence of Gastrointestinal Ulceration and Cytogenetic Aberration of Trisomy 8 as Typical Features of Behçet's Disease Associated with Myelodysplastic Syndrome: A Series of 16 Consecutive Chinese Patients from the Shanghai Behçet's Disease Da
P2860
Q33405487-45905F48-5112-4A7D-8CA8-6B70AB1AF0BEQ36612675-950FFB2E-695B-49AB-9CF6-011B2F8D9082Q36721793-4F22916D-7F9E-4B9B-BA44-9DC3F30C9F1DQ37293324-C5FBACDA-5D7C-4A4F-BDB8-094946D51BD0Q37377901-34B45C41-0285-423F-805D-C186AC5B4C91Q38235662-F36C4502-1239-4694-8A89-A42197AD9E64Q38341998-AFA61EFD-1B17-467D-A375-70C32848351BQ38527837-698825BF-B4BD-4D39-9426-B0FEE43250B9Q38965973-057DCFF9-BE49-4597-9228-01BDE8D10010Q46960830-568A81D6-D2C7-4066-848E-5511354EAEA8Q47301676-432DDD13-C744-46D7-BE8C-0C16EA124197Q47782255-BC0D6F3E-05B8-4879-A3D0-B7218E4882CEQ53150651-06B99108-2B75-4C54-82BD-74363F35F923Q53561569-A225281A-0E33-4998-BA7C-49564E0F1AD1Q54384826-F035ABA2-DB14-441E-9E12-07BC8D613B0BQ55291697-E3911153-5DF2-4259-B0EE-2D2D9A7249CD
P2860
Incidence and prognostic significance of karyotype abnormalities in de novo primary myelodysplastic syndromes: a study on 331 patients from a single institution.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Incidence and prognostic signi ...... nts from a single institution.
@en
Incidence and prognostic signi ...... nts from a single institution.
@nl
type
label
Incidence and prognostic signi ...... nts from a single institution.
@en
Incidence and prognostic signi ...... nts from a single institution.
@nl
prefLabel
Incidence and prognostic signi ...... nts from a single institution.
@en
Incidence and prognostic signi ...... nts from a single institution.
@nl
P2093
P2860
P356
P1433
P1476
Incidence and prognostic signi ...... nts from a single institution.
@en
P2093
Bernasconi C
Bernasconi P
Calatroni S
Caresana M
Cavigliano PM
Giardini I
Lazzarino M
P2860
P2888
P304
P356
10.1038/SJ.LEU.2403806
P577
2005-08-01T00:00:00Z